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Abstract 
The molecular mechanisms underlying the drug-solubilizing properties of γ-cyclodextrin were 
explored using hydrocortisone as a model drug. The BS-type phase-solubility diagram of 
hydrocortisone with γ-cyclodextrin was thoroughly characterized by measuring the concentrations 
of hydrocortisone and γ-cyclodextrin in solution and the solid phase. The drug-solubilizer 
interaction was also studied by isothermal titration calorimetry from which a precise value of the 
1:1 binding constant (K11 = 4.01 mM-1 at 20°C) was obtained. The formation of water-soluble 1:1 
complexes is responsible for the initial increase in hydrocortisone solubility while the precipitation 
of entities with a 3:2 ratio of γ-cyclodextrin:hydrocortisone is responsible for the plateau and the 
ensuing strong decrease in solubility once all solid hydrocortisone is used up. The complete phase-
solubility diagram is well accounted for by a model employing the 1:1 binding constant and the 
solubility product of the precipitating 3:2 entity (KS32 = 5.51 mM5). For such systems, a small 
surplus of γ-cyclodextrin above the optimum concentration may result in a significant decrease in 
drug solubility, and the implications for drug formulations are briefly discussed. 
 
 
 
Keywords: cyclodextrin; phase-solubility; calorimetry; hydrocortisone; inclusion complex; binding 
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1. Introduction 
Addition of cyclodextrins (CDs) is an often used formulation strategy to increase the apparent 
aqueous solubility of poorly soluble drugs (Williams et al., 2013). Formation of water-soluble 
inclusion complexes between drug and cyclodextrin increases the amount of drug in solution but 
other mechanisms may also contribute to the increased drug solubility. Both CDs and their 
complexes may form aggregates in which drug molecules are included, similar to solubilisation of 
drugs by incorporation into micelles. The exact contribution of CD aggregates to the increased drug 
solubility is difficult to quantify but it is nevertheless anticipated that aggregate formation can be 
exploited as a new type of drug delivery system (Ryzhakov et al., 2016). It is clear, however, that a 
more thorough understanding of the aggregation phenomenon is required. 
Hydrocortisone (HC) solubilised by CDs is an often used model system for the study of CD 
aggregates and their impact on drug solubility (Jansook et al., 2010; Jansook and Loftsson, 2008; 
Messner et al., 2011a, 2011b; Saokham et al., 2016). In the case of modified cyclodextrins (e.g. 
hydroxypropylated β- and γCDs) the equilibrium concentration of hydrocortisone increases linearly 
with the CD concentration resulting in a so-called AL-type phase solubility (PS) diagram, using the 
classification system of Higuchi and Connors (Higuchi and Connors, 1965). For the natural β- and 
γCDs, BS-type PS diagrams have been reported which are characterized by an initial linear increase 
in the amount of dissolved drug followed by a plateau where the concentration of dissolved drug is 
independent of the CD concentration. After the plateau, the drug concentration decreases with 
increasing amounts of CD (Figure 1). From a formulation point of view, BS-type systems are 
problematic as just the right amount of CD is required to obtain maximum drug solubility and 
addition of too much CD (relative to the amount of drug) may significantly lower the amount of 
dissolved drug. According to the traditional interpretation (Higuchi and Connors, 1965) BS-type PS 
diagrams occur due to formation of complexes with a limited aqueous solubility but more recent 
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studies suggest that formation of nano- and micrometer-sized aggregates also play an important role 
(Messner et al., 2011a; Saokham and Loftsson, 2017). However, a detailed mechanistic description 
involving aggregates has not been provided. The present work aims to fill in this gap via a thorough 
characterization of the system and subsequent modelling of the experimental data.  
In order to understand the mechanisms that determine the shape of BS-type PS diagrams we have used 
a novel multifaceted experimental approach combining traditional PS analysis and Isothermal 
Titration Calorimetry (ITC). As shown in 1965 by Higuchi and Connors, BS-type PS diagrams can 
be analyzed to provide the stoichiometry and binding constant of the formed complexes. More 
modern techniques are also available to determine the binding constants, e.g. ITC which can provide 
precise estimates of binding constants and stoichiometries of drug:CD complexes. ITC can normally 
only be used in the lower concentration range as the technology requires both of the complexing 
species to be in solution, i.e. the drug solubility in water can define the limitation. So while ITC is 
very precise for the initial part of the BS-type PS diagram it fails in characterizing the following parts 
where the species are present at higher concentrations. This underlines the importance of multiple 
characterization approaches for complicated PS diagrams. 
Traditionally, PS diagrams are constructed for only one of the components in solution, the drug, and 
the total concentration of drug in solution is plotted as a function of added CD. Measuring the 
concentration of the complexing agent is in principle not necessary and is rarely done. However, 
quantifying the amount of CD in solution allows for a more detailed mechanistic picture in terms of 
the composition of the precipitate and the identity of the molecular species in solution. 
Unfortunately, CDs are not easy to quantify as they contain no chromophores or fluorophores, and 
researchers have resorted to other analytical techniques, e.g. measuring the refractive index 
(Jansook et al., 2010). Recently, a method have been developed where the concentration of CDs is 
determined accurately by HPLC coupled to a Charged Aerosol Detector (Saokham and Loftsson, 
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2015), thereby assisting the interpretation of the PS diagram. In addition to quantifying the amount 
of drug and γCD in solution, we also characterize the overall composition of the precipitate as well 
as the amount of uncomplexed drug in the precipitate. By combining the information from these 
complementary analytical techniques we intend to obtain a more complete picture of the molecular 
mechanisms that determine the features of BS-type PS diagrams. Once a mechanistic model is 
established, it can provide a full map of the formulation space and thereby define the optimal 
formulation space for a compound with a BS-type PS diagram, in the present case HC.  
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2. Theoretical Background 
The analysis of BS-type phase diagrams was pioneered by Higuchi and Connors in 1965 (Higuchi 
and Connors, 1965), but a more exhaustive and formal mathematical treatment has later been 
developed which also takes various higher-order complexes into account (Zughul and Badwan, 
1998, 1997; Zughul, 2007). 
Complex usually refers to molecular assemblies formed by combination of substrates (S) and 
ligands (L), and in most cases complex formation is a reversible process. PS diagrams are typically 
constructed by mixing a constant amount of solid substrate (in this work HC) with a medium 
containing varying concentrations of solubilizer or ligand, Lt, (in this work γCD) and then 
measuring the equilibrium concentration of dissolved solute, Seq. If one of the formed complexes 
has a limited solubility and starts precipitating from the solution above a given concentration of 
solubilizer BS-type diagrams are observed. These are divided into 3 regions as sketched in Figure 1. 
 
Figure 1 
 
Region I: Total concentration of solute in solution, Seq, increases with increasing concentration of 
solubilizer. Precipitate consists of solid solute. 
Region II: The solubility limit of one of the formed complexes is exceeded, and the concentrations 
of all species in solution are constant. Precipitate consists of solid solute and precipitated 
complexes. 
Region III: All solid S is depleted and exists as free and complexed S in the solution and as 
complexed S in the precipitate. Seq decreases with increasing Lt due to the gradual conversion of 
free S and soluble complexes to precipitated complex. 
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In each of the 3 regions the following mass balances apply for the molecular species in solution: 
Seq = [S] + [LS] + …    (1) 
Leq = [L] + [LS] + …    (2) 
Where the concentration of 1:1 complexes, [LS], is related to the concentrations of free solutes, [S], 
and hosts, [L], via the equilibrium constant: 
[LS] = K11 . [L] . [S]    (3) 
The (…)’s in equations 1 and 2 represent possible higher-order complexes, LxSy. If these are 
present, their concentrations are given as: 
[LxSy] = Kxy . [L]x . [S]y    (4) 
These equations pertain to each of the 3 regions but the mathematical description of the PS diagram 
requires additional restrictions which are specific to each region. In a standard PS diagram Seq is 
plotted versus the known initial concentration of ligand, Lt, in the liquid phase. In order to express 
Seq as a function of Lt it is necessary to restrict some of the variables in equations 1-4. These 
restrictions are specific to each of the 3 regions: 
 
Region I: Solid solute is present, and the concentration of free solute, [S], is therefore equal to its 
intrinsic solubility S0 (its solubility in the aqueous medium when no ligand (i.e. cyclodextrin) is 
present). As no host has precipitated, Leq is equal to the known concentration Lt. Seq can therefore 
be expressed as a function of Leq, the constant S0, and the equilibrium constants. 
 
Region II: Solid solute and precipitated complex are present, and so [S] = S0, and the concentration 
of precipitating complex is equal to its solubility, SXY. Seq is a function of the constants S0, SXY, and 
the complex equilibrium constants and is therefore itself a constant. 
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Region III: Precipitated complex is present and its concentration is equal to its solubility, SXY. Now 
there are too many unknowns for the equations to be solved so another requirement has to be 
introduced: 
Lt = Leq + x . LxSyprec.    (5) 
St = Seq + y . LxSyprec.    (6) 
Subtracting x . St from y . Lt eliminates the amount of precipitated complex, LxSyprec., and results in: 
y . Lt – x . St = y . Leq – x . Seq   (7) 
Inclusion of equation 7 allows Seq to be calculated in region III as a function of the variable Lt, the 
constants St, SXY, and the complex equilibrium constants. 
 
From equations 1-3 and the region-specific requirements the equilibrium concentrations of solute 
and ligand, Seq and Leq, can be expressed as a function of the initial concentration of ligand, Lt. 
These expressions are given in Table 1 for the 1:1 model together with the boundaries between the 
regions. Plotting these equations produces a theoretical PS diagram with a shape determined by S0, 
S11, K, and St. Similarly, equations 1-4 may be solved for systems that form higher-order complexes 
but often they can only be solved numerically. More information on how to solve these equations 
and construct PS diagrams is provided as Supplementary material. 
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Table 1 Overview of the equations that constitute the solution to the 1:1 model. The first row shows the starting points of the 
regions. Region I, for example, starts at Lt = 0 mM and ends at Lt = S11(1+1/KS0) where region II sets in. 𝛥𝛥 = Lt – St. 
 Region I Region II Region III 
Onset of 
region 𝐿𝐿𝑡𝑡 = 0 𝐿𝐿𝑡𝑡 = 𝑆𝑆11 �1 + 1𝐾𝐾 ∙ 𝑆𝑆0� 𝐿𝐿𝑡𝑡 = 𝑆𝑆11𝐾𝐾 ∙ 𝑆𝑆0 + 𝑆𝑆𝑡𝑡 − 𝑆𝑆0 
Equilibrium 
concentration 
of solute, Seq 
𝑆𝑆0 + 𝐿𝐿𝑡𝑡 ∙ 𝐾𝐾 ∙ 𝑆𝑆0𝐾𝐾 ∙ 𝑆𝑆0 + 1 𝑆𝑆0 + 𝑆𝑆11 𝑆𝑆11 − Δ ∙ 𝐾𝐾 − �Δ2 ∙ 𝐾𝐾2 + 4 ∙ 𝑆𝑆11 ∙ 𝐾𝐾2𝐾𝐾  
 
Equilibrium 
concentration 
of ligand, Leq 
𝐿𝐿𝑡𝑡 𝑆𝑆11 �1 + 1𝐾𝐾 ∙ 𝑆𝑆0� 𝑆𝑆11 + Δ ∙ 𝐾𝐾 +�Δ2 ∙ 𝐾𝐾2 + 4 ∙ 𝑆𝑆11 ∙ 𝐾𝐾2𝐾𝐾  
  
10 
 
3. Materials and Method 
3.1 Isothermal Titration Calorimetry (ITC) 
ITC experiments were performed on a VP-ITC (Malvern Instruments, Malvern, UK). A solution of 
10 mM γCD (purity ≥ 98%, Sigma-Aldrich, St. Louis, MO, USA) in Milli-Q water was injected in 
10 μL aliquots into a solution of 0.5 mM HC (purity ≥ 98%, Sigma-Aldrich) at 10, 25, 40, and 
55°C. Heat signals were integrated using the ITC data analysis application for Origin 7.0 that was 
provided with the calorimeter. The integrated heats and the cell concentrations were exported and 
analyzed using in-house Matlab scripts to yield the thermodynamic parameters of the complexation 
equilibrium (Schönbeck et al., 2012). 
 
3.2 Phase Solubility (PS) 
Stock solutions of γCD were made by dissolving γCD (CycloLab, Hungary) in Milli-Q water. The 
concentrations were corrected for the water content of the γCD (10.5% w/w). Approximately 25.4 
mg of microcrystalline HC (Fagron, The Netherlands) was added to each of the 4 ml glass vials, 
corresponding to a concentration of around 35 mM upon addition of 2 ml of solvent of varying 
concentrations of γCD in the range 0-140 mM. The mixtures were sonicated for 40 minutes at 60°C 
and left to equilibrate at room temperature (around 20°C) for six days under constant shaking. 
After equilibration, the vials were centrifuged, and the supernatant was removed with a plastic 
Pasteur pipette and filtered through a 0.45 μm reconstituted cellulose filter. After appropriate 
dilution, the contents of γCD and HC were determined by HPLC-CAD. The vials containing the 
precipitate were weighted, dried in vacuo at 55°C for 5 hours and weighted again to calculate the 
mass loss and thereby the small amount of remaining supernatant that for practical reasons had not 
been separated from the precipitate. A fraction of the dry precipitate was dissolved and analyzed for 
its content of γCD and HC by HPLC-CAD. 
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3.3 Quantification by HPLC-CAD 
The total contents of γCD and HC in the samples were quantified by HPLC connected to a Charged 
Aerosol Detector (CAD) (Corona Ultra RS, Dionex, Sunnyvale, CA) as previously described 
(Saokham and Loftsson, 2015). 70/30% V/V methanol/water was used as mobile phase and the 
analytes were separated on a C18 column thermostated at 30°C. The CAD was operating at 30°C. 
Three injections were made for each sample, and the standard deviation of the peak areas was in 
most cases below 1%. The standard curves for γCD and HC were highly non-linear and were 
generated by fitting a function of the form y = a + bxc to at least 8 data points in the range 0.05-4 
mM for γCD and 0.04-1.67 mM for HC. 
 
3.4 Differential Scanning Calorimetry (DSC) 
5-7 mg of the dry precipitates were precisely weighted out in aluminium crucibles, and 
thermograms were recorded on a DSC 214 (NETZSCH, Selb, Germany). Samples were heated from 
room temperature to 270°C at a rate of 20 K/min.  
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4. Results 
4.1 Isothermal Titration Calorimetry 
The calorimetric titrations of HC with γCD were exothermic at all temperatures although the heat 
signals were small at 10°C but increased with increasing temperature. A single global fit of all 
calorimetric titrations was conducted with a binding model that assumes a single type of binding 
site on HC and assumes that the heat capacity change, ΔCp, is temperature-independent (Schönbeck 
et al., 2012). The fitting parameters are the stoichiometry, N, the binding constant at 20°C, K11, the 
binding enthalpy at 20°C, ΔH, and the change in heat capacity, ΔCp. As shown in Figure 2, this 
approach yielded good fits to all of the calorimetric data and provided precise binding parameters. 
The stoichiometry is close to unity, indicating the formation of 1:1 complexes. 
 
Figure 2 
 
4.2 Phase solubility studies 
Plotting the equilibrium concentration of dissolved HC (Seq) as a function of the initial 
concentration of γCD (Lt) results in a BS-type PS diagram (Figure 3) characterized by three well-
defined regions. The plot of the equilibrium concentration of γCD (Leq) (Figure 3) also has three 
regions. In region I, a linear increase in both Seq and Leq is observed. The intrinsic solubility of HC, 
S0, was determined to 0.728 ± 0.006 mM (n = 3). The plateau in region II stretches from around 9 
mM to 49 mM and is followed by region III where a strong decrease in Seq and a strong increase in 
Leq is observed. Peaking concentrations are observed for both Seq and Leq in the beginning of the 
plateau and are ascribed to super-saturation of the precipitating complex. If these peaks are ignored, 
the concentrations of HC and γCD in region II are 7.1 ± 0.1 mM and 8.6 ± 0.3 mM, respectively. 
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Figure 3 
 
From the length of the plateau in region II, the total amount of HC added to the vials, and the 
measured concentration of HC at the plateau, the stoichiometry of the precipitating entity is 
calculated (Higuchi and Connors, 1965) to be 1.43, or approximately 1.5 γCDs per HC. 
 
Since the total amounts of HC and γCD in the vials are known, the amounts in the precipitate can be 
calculated. The ratio of γCD to HC in the precipitate is plotted in Figure 4. In region I, the 
precipitate presumably consists of pure undissolved HC while in region II two solid phases exist: 
pure undissolved HC and precipitated complex. The ratio of γCD to HC increases in region II as 
solid HC is gradually converted into precipitated complex. In region III, the precipitate no longer 
contains a solid phase of pure HC so the relatively constant ratio shows that precipitation continues 
at a fixed stoichiometry around 1.6-1.7. 
 
Figure 4 
 
4.3 Analysis of precipitate 
The amounts of HC and γCD in the precipitate were analyzed by HPLC. Since it was impossible to 
remove all supernatant from the precipitate, the contributions from the remaining supernatant was 
corrected for by using the mass loss upon drying (from which the remaining volume of supernatant 
can be estimated) and the known concentrations in the supernatant. The results are also plotted in 
Figure 4 and agree well with the abovementioned indirect estimate of the composition of the 
precipitate. 
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The DSC thermogram of pure HC showed a melting peak at 228°C, which is close to a previously 
reported value of 223.3°C (Marciniec et al., 2003). This peak also appeared in the thermograms of 
precipitates from region I and II but not region III, confirming the assumption that a solid phase of 
pure HC is present in region I and II but not in region III. In principle, the amount of HC present as 
pure HC can be calculated from the area of the melting peak. Because the total amount of HC in the 
precipitate is already known, the amount of HC present as complexes can be calculated, and the 
stoichiometry of the precipitated complexes can be calculated throughout region II. Due to poor 
reproducibility, however, sufficiently precise values of the melting heats could not be obtained. 
Hence, no precise values of the stoichiometry of the precipitated complexes could be obtained in 
region II. Nevertheless, it was clear that the content of pure HC in the precipitate gradually 
decreased throughout region II in accordance with the assumptions described above. 
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5. Discussion 
The PS diagram of the HC-γCD system is of the Bs-type. The conventional interpretation of such 
diagrams involves the precipitation of a poorly soluble complex. The results obtained in the present 
work clearly show that γCD and HC precipitate in a ratio higher than 1:1 and most likely 1:1.5, 
suggesting the precipitation of γCD:HC complexes with a 3:2 stoichiometry. The conclusion from 
the ITC analysis, however, strongly suggest that HC and γCD form 1:1 complexes. It is therefore 
worth considering to what extent the 1:1 model can explain the data. 
 
5.1 Compatibility with 1:1 binding model 
If only 1:1 complexes contribute to the increase in solubility in region I, the 1:1 binding constant 
can be obtained from the slope, α, of the initial linear part of the solubility curve and S0 (Higuchi 
and Connors, 1965): 
𝐾𝐾11 = 𝛼𝛼(1−𝛼𝛼)∙𝑆𝑆0    (5) 
Since it is not clear exactly when region II starts, the calculation of the slope is only based on the 
solubility data where Lt is 0, 3.0, and 6.2. These data points lie perfectly on a straight line (r2 = 
0.99997) with a slope that translates to K11 = 3.63 mM-1. This value is in good agreement with the 
ITC results, and the data in region I are thus compatible with a model where only 1:1 complexes are 
formed. 
 
The 1:1 model predicts the relation between Leq and Seq in region II (and in region I) to be: 
𝑆𝑆𝑒𝑒𝑒𝑒 = 𝑆𝑆0 + 𝐿𝐿𝑒𝑒𝑒𝑒 ∙ 𝐾𝐾11∙𝑆𝑆0𝐾𝐾11∙𝑆𝑆0+1    (6) 
Using the value for the γCD plateau as Leq, the binding constant from ITC as K11, and the measured 
S0, yields St = 7.1 mM which in excellent agreement with the observed value of the HC plateau in 
16 
 
region II. The heights of the HC and γCD plateaus in region II are thus perfectly compatible with 
the 1:1 model but, as mentioned above, the length of region II clearly shows that the stoichiometry 
of the precipitating complexes is not 1:1. The data in region III are not compatible with a 1:1 model 
either. If the limited solubility of the 1:1 complex is the cause of the plateau in region II, the 
concentration in region III should theoretically stay above the height of the plateau minus S0 
(Higuchi and Connors, 1965), which is around 6.4 mM. However, the concentration of HC in 
region III drops significantly below 6.4 mM and reaches a minimum of 0.819 ± 0.008 mM at Lt = 
140 mM. These inadequacies of the 1:1 model are illustrated in Figure 5 where the predictions of 
the 1:1 model are plotted together with the experimental data. 
 
Figure 5 
 
5.2 Compatibility with 3:2 model 
From the discussion above it is clear that the 1:1 model is insufficient to describe all of the observed 
features in region II and III. The experimental data indicate that γCD and HC precipitate in a 3:2 
ratio so it is natural to include 3:2 complexes in the mass balances. In the 1:1 model, it was assumed 
that the solutes precipitate due to the limited solubility of the formed 1:1 complexes but in the 3:2 
model precipitation is caused by the limited solubility of the 3:2 complexes. Formation of 3:2 
complexes may occur in a stepwise fashion, and a rigorous treatment should include all possible 
molecular species in the mass balances, i.e. complexes with 1:1, 1:2, 2:1, 2:2, and 3:2 
stoichiometry. However, this would add considerable complexity to the model. For simplicity, the 
presently described 3:2 model considers only the presence of complexes with a 1:1 and 3:2 
stoichiometry. 
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In principle, the experimental determination of both St and Lt in region II can be exploited to 
calculate the solubility of the 3:2 complex, S32, and the additional equilibrium constant, K32. To 
calculate S32 the mass balances in equations 1 and 2 are first modified by substituting [CD] with 
1/(K11.S0), [S] with S0, and [L3S2] with S32: 
Seq = S0 + [LS] + 2.S32    (7)  
Leq = ε.[LS] + 3.S32    (8) 
where ε = 1 + 1/(K11.S0). Subtracting ε.Seq from Leq eliminates [LS] and allows S32 to be isolated: 
𝑆𝑆32 = 𝐿𝐿𝑒𝑒𝑒𝑒−𝜀𝜀∙�𝑆𝑆𝑒𝑒𝑒𝑒−𝑆𝑆0�3−2𝜀𝜀     (9) 
Unfortunately, both the numerator and the denominator are calculated as differences between 
numbers that are similar in magnitude and thus become very small. Therefore, even small errors in 
the experimental values of Leq and Seq result in large errors in S32. For example, if Leq = 8.6 mM and 
Seq = 7.1 mM, then S32 = 0.14 mM. If Leq = 8.9 mM, then S32 = 1.1 mM. With the current standard 
errors on Leq and Seq at the plateau no reliable estimate of S32 can be made. 
To calculate K32, the concentration of 3:2 complexes are eliminated from the mass balances in 
equations 1 and 2, [S] is substituted with S0, and [L:S] is replaced by K11.S0.[L]: 
2.Leq – 3.Seq = 2.[L].(2 - K11.S0) – 3.S0   (10) 
From this, [L] can be isolated: [𝐿𝐿] = 2∙𝐿𝐿𝑒𝑒𝑒𝑒−3∙�𝑆𝑆𝑒𝑒𝑒𝑒−𝑆𝑆0�
2−𝐾𝐾11∙𝑆𝑆0
    (11) 
This can then be inserted into the expression for K32: 
𝐾𝐾32 = 𝑆𝑆32𝑆𝑆02∙[𝐿𝐿]3     (12) 
However, since S32 cannot be determined precisely neither can K32. As an alternative equilibrium 
constant, the solubility product of the 3:2 complex, KS32, can be estimated without the use of S32: 
KS32 = [L]3.[S]2    (13) 
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In region II, [S] can be substituted with S0: 
𝐾𝐾32
𝑆𝑆 = [𝐿𝐿]3 ∙ 𝑆𝑆02    (14) 
Using Leq = 8.6 mM, Seq = 7.1 mM, S0 = 0.728 mM, and K11 = 4.01 mM-1 in eq. 11 to calculate [L], 
we obtain from eq. 14 that KS32 = 4.8 mM5. It turns out (see below) that S32 must be very small and 
might even be zero. An imprecise value of S32 results in an imprecise value of K32, and if the 
concentration of 3:2 complexes is zero, it does not make sense to define K32. The solubility product, 
KS32, has the advantage that it does not require the presence of 3:2 complexes in the solution. It just 
assumes that γCD and HC precipitate in a 3:2 ratio. It is worth noting that KS32 can be expressed in 
terms of K32 and S32. KS32 = [L3S2] / K32 which in region II and III simplifies to KS32 = S32 / K32. 
 
The predictions of the 3:2 model are shown in Figure 5. In general, it explains the experimental 
observations well except for the high concentrations in the beginning of region II which are 
ascribed to supersaturation. The low measured concentrations of HC at high CD concentrations 
(0.827 ± 0.008 mM at Lt = 140 mM) require a low value of S32 as the predicted HC concentrations 
in region III are shifted upwards by 2.S32. Even though S32 is set to zero in Figure 5, the 
experimental data lie slightly below the predicted line. S32 = 0 implies that the concentration of 3:2 
complexes is always zero, and this simplifies the model such that KS32 is the only adjustable 
parameter. S0 is measured directly and K11 is obtained from the ITC measurements. In Figure 5, 
KS32 is chosen such that the predicted concentration of HC at the plateau matches the experimental 
value (7.1 mM). The good prediction of the remaining data in region III, with respect to both γCD 
and HC, is a strong validation of the model. 
 
The question remains what exactly precipitated from the solution? Since the experimental errors do 
not allow a firm conclusion to whether or not a 3:2 complex exists in solution, it seems a bit hasty 
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to assume the precipitation of a 3:2 complex. What seems to be certain is that γCD and HC 
precipitate in a 3:2 ratio. This could be in the form of a 3:2 complex, a 4:6 complex or any other 
shape whose solubility product has the form [L]3*n . [S]2*n because then [L]3 . [S]2 will be a constant. 
In principle, γCD and HC could form a co-crystal of uncomplexed γCD and HC but it could also be 
a co-crystal of 1:1 complexes and uncomplexed γCD (in a 2:1 ratio). The possibilities are many. 
 
Precipitation of 3:2 γCD complexes were previously reported for a range of steroid hormones, 
including hydrocortisone (Uekama et al., 1982). This conclusion was solely based on the length of 
the region II plateau of the PS diagram. The present study confirms this observation and further 
shows that the low solubility of this complex is responsible for the decrease in drug solubility in 
region III. Most of the HC in solution exists in the form of 1:1 complexes while the 3:2 complexes 
contribute very little to the HC solubility, if at all. It is worth noting that the 3:2 model accurately 
describes the experimentally determined PS diagrams of both HC and γCD without introducing 
aggregates into the models. This suggests that aggregates have very little impact on the solubility of 
drug and CD, in contrast to previous speculations (Messner et al., 2011a; Saokham and Loftsson, 
2017). 
 
The present work provides a complete mechanistic model of the solubilisation of HC by γCD and 
can therefore be used to make quantitative predictions regarding the solubility of HC in 
formulations with γCD now that the parameters in the model have been determined (S0 = 0.728 
mM, K11 = 4.01 mM-1, KS32 = 5.51 mM5). This is exploited in the following section. 
 
5.3 Implications for drug formulation: 
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The descending part of BS-type PS diagrams is of course problematic when trying to improve the 
aqueous solubility of a drug. The fact that the transition from region II to III is not fixed but 
depends on the initial amount of added drug only exacerbates the problem. From the PS diagram in 
Figure 3, one may falsely conclude that 40 mM of γCD can dissolve 7.1 mM of HC but this is only 
the case if solid HC is present such that [S] = S0. If all HC is dissolved, the system is in region III 
where a large excess of γCD may cause significant amounts of HC to precipitate together with CDs. 
When testing the solubility of a drug in various media, excess amounts of drug are added to the 
solutions to obtain solutions that are saturated with drug. Such solubility experiments will therefore 
show that the solubility in a γCD solution (e.g. 40 mM) is 7.1 mM. However, if one afterwards try 
to dissolve the amount of HC corresponding to 7.1 mM in 40 mM γCD, a significant amount of HC 
will be found to precipitate with γCD, and only a minor fraction will remain in solution (see Figure 
6). In the latter case there is no excess of solid drug and therefore the system is in region III where 
Seq will always be lower than the plateau value and decrease towards the solubility of the 
precipitating complex in the limit of very large surplus of CDs. If the precipitating complex is the 
same as the solubilizing complex the descending curve in region III is in general not a major 
problem as Seq will not go below its plateau value minus S0. This is the case for the 1:1 model as 
shown in Figure 5. But in the present case Seq is limited by the solubility product, KS32, and goes 
towards zero with increasing Lt. 
 
The negative effect of having too high a concentration of γCD in the medium is shown in the 
reverse PS diagram in Figure 6 where the initial concentration of γCD is set to 40 mM. It is seen 
that if 10 mM of HC is added to the solution less than 2 mM is solubilized, the rest is converted to 
precipitated 3:2 complex. 
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Figure 6 
 
The inverse PS diagram in Figure 6 is constructed from the determined values of S0, K11, and KS32. 
The detailed construction of reverse PS diagrams are described in the Supplementary material. Such 
a diagram is useful as it contains information on what happens when a given amount of drug is 
attempted dissolved in a dissolution medium containing a certain concentration of CD (40 mM γCD 
in Figure 6). Will there be any precipitate and what will the precipitate consist of? The dissolution 
rate of solid HC may be different from solid 3:2 complex and therefore the composition of the 
precipitate may be important. Like the normal PS diagram the inverse PS diagram can be divided 
into different regions. In the first region, termed region IV, all of the added drug is dissolved since 
the product [L]3 . [S]2 is smaller than the solubility product, KS32. Therefore, there is no precipitate, 
and Seq is given by a straight line with a slope of unity. Region IV continues until the point where 
[L]3 . [S]2 = KS32, beyond which a fraction of the added HC will be converted to solid 3:2 complex. 
Since the precipitate only consists of solid 3:2 complex the system is in the above mentioned region 
III. At some point, when enough HC is added to the dissolution medium, there is not enough CD in 
the solution to convert all of the undissolved HC to solid 3:2 complex and the solid phase will 
consist of solid HC and solid 3:2 complex. At that point the system is in the above mentioned 
region II. Unlike the normal PS diagram, the first transition, from region IV to region III, is not 
fixed but depends on the concentration of CD in the medium. Higher CD concentrations cause the 
transition to occur at lower values of St. 
 
For some purposes it may be desirable that the solution contains a maximum concentration of drug 
but no particles or precipitate. How can this be achieved? In region II where the precipitate consists 
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of solid complex and drug the solution contains the maximum amount of drug. Thus, if drug and 
CD are mixed in the amounts corresponding to their concentrations in region II there will be no 
precipitate at equilibrium. In the case of HC and γCD at 20°C the amounts should correspond to 7.1 
mM and 8.6 mM, respectively, to obtain a maximum concentration of HC and avoid any solid 
phase. Rather than mixing these exact amounts of drug and CD such a solution is more easily 
obtained by adding sufficient amounts of drug to the CD medium to ensure that solid drug and solid 
complex is present, followed by removal of the precipitate. The formulation at this point would not 
be very robust and very sensitive to variations in one of the two components, so the specification for 
the drug product should be carefully considered. 
 
The descending part of the HC:γCD PS diagram descends to a very low concentration of HC and 
this poses a difficulty when using γCD as a solubilizer for HC. But is it a general feature of γCD 
that it forms BS-type diagrams where region III descends to such low values? If that is the case one 
should be very careful when using γCD as a solubilizer as too high concentrations of γCD results in 
very low concentrations of dissolved drug. An extensive study of the interaction between CDs and 
steroid hormones showed that natural βCD and γCD formed BS-type PS diagrams with most of the 
hormones (Uekama et al., 1982). Judging from the length of the plateau region, γCD precipitated in 
a 3:2 ratio with most of the hormones and thereby seemed to behave similar to the HC:γCD system. 
Care must therefore be taken when using γCD as a solubilizer for this class of drugs although the 
CD may work very well for other classes of compounds. The present study clearly demonstrated the 
value of constructing a PS diagram when using CDs as a solubilizing excipient in order to define 
the optimal solubility and a robust formulation.  
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6. Conclusion 
The solubility of hydrocortisone (HC) was measured in water containing varying concentrations of 
γCD. The resulting BS-type phase-solubility diagram was described within the theoretical 
framework laid out by Higuchi and Connors. The initial linear increase in the solubility at low 
concentrations of γCD was caused by the formation of a water-soluble 1:1 complex but the plateau 
was caused by precipitation of another entity with the stoichiometry 3:2 γCD:HC. The solubility 
product of the 3:2 entity quantitatively accounted for the decrease in HC solubility at high γCD 
concentrations. Within the experimental errors it was not possible to conclude whether or not a 3:2 
γCD:HC complex existed in solution at low concentrations. γCD and HC may precipitate as larger 
units as long as the ratio of γCD to HC is 3:2. 
Care must be taken when co-formulating HC with natural γCD as high concentrations of γCD may 
severely reduce the amount of dissolved HC. Since steroid hormones seem to interact with γCD in a 
similar manner this advice is extended to this class of drugs, but at present it is unclear whether it is 
a general feature of natural γCD. 
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Figures: 
 
Figure 1 Illustration of a BS-type PS diagram. S0 is the intrinsic solubility of the drug. For each of 
the three regions the relevant equilibria and the composition of the precipitate are shown. S, L and 
S:L denotes drug, ligand and complex in solution. 
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Figure 2 Global fit of 4 titrations of HC with γCD in the range 10-55°C. 
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Figure 3 Phase-solubility diagram of the HC-γCD system in water. Due to the different 
concentration ranges, the measured concentrations of HC and γCD are given on the left and the 
right axis, respectively. 
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Figure 4 Ratio of γCD to HC in the precipitate from the phase-solubility study. The ratio was 
calculated indirectly by subtracting the measured concentrations in the solution phase from the 
total amounts, and was also determined directly by analysing the precipitate. The dotted horizontal 
line is a guide for the eye and has a value of 1.5. 
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Figure 5 Predictions of the 1:1 model (dotted lines) and the 3:2 model (solid lines) together with 
experimental data (open symbols). For the 1:1 model, the plotted functions are given in the Table 1. 
For the 3:2 model, the construction of the theoretical PS diagram is explained in the Supplementary 
material. In the 1:1 model, the used parameters were St = 35 mM, S0 = 0.728 mM, S11 = 6.372 mM, 
and K11 = 4.01 mM-1. The 3:2 model used the same values of St, S0 and K11 in addition to KS32 = 
5.51 mM5 and S32 = 0 mM. 
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Figure 6 The amount of HC in solution depends on the amount of added HC. The figure shows the 
predicted amount of dissolved HC as a function of the added amount of HC in the case where the 
dissolution medium initially contains 40 mM γCD. It can be read from the plot that if 7.1 mM HC is 
added to a 40 mM γCD solution only little more than 1.5 mM of HC will dissolve. 
 
